ScholarIQanswers from OpenAlex & ORCID
Ali Tafreshi
ResearcherPublications, citations & collaboration network
Ali Tafreshi is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Ali Tafreshi have?
ScholarIQindexed works
Ali Tafreshi has 150 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Ali Tafreshi have?
ScholarIQcitation count
Ali Tafreshi has 26,380 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Ali Tafreshi?
ScholarIQh-index
Ali Tafreshi has an h-index of 35 in OpenAlex.
What is the i10-index of Ali Tafreshi?
ScholarIQi10-index
Ali Tafreshi has an i10-index of 71 in OpenAlex.
What is the ORCID of Ali Tafreshi?
ScholarIQorcid
The ORCID for Ali Tafreshi is on the source record.
What is the OpenAlex record for Ali Tafreshi?
ScholarIQopenalex
The OpenAlex for Ali Tafreshi is on the source record.
What are the most-cited papers on Ali Tafreshi?
ScholarIQmost cited works
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
Martin Reck, Delvys Rodríguez‐Abreu, Andrew Robinson, Rina Hui, Tibor Csőszi, Andrea Fülöp, Maya Gottfried, Nir Peled, Ali Tafreshi, Sinéad Cuffe, Mary O’Brien, Suman Rao, Katsuyuki Hotta, Melanie A. Leiby, Gregory M. Lubiniecki, Yue Shentu, Reshma Rangwala, Julie R. Brahmer
Identifying Medical Diagnoses and Treatable Diseases by Image-Based Deep Learning
Daniel Kermany, Michael H. Goldbaum, Wenjia Cai, Carolina C. S. Valentim, Huiying Liang, Sally L. Baxter, Alex McKeown, Ge Yang, Xiaokang Wu, Fangbing Yan, Justin Dong, Made K. Prasadha, Jacqueline Pei, Magdalene Yin Lin Ting, Jie Zhu, Christina Li, Sierra Hewett, Jason Dong, Ian Ziyar, Alexander Shi, Runze Zhang, Lianghong Zheng, Rui Hou, William Y. Shi, X Fu, Yaou Duan, Viet Anh Nguyen Huu, Cindy Wen, Edward D. Zhang, Charlotte L Zhang, Oulan Li, Xiaobo Wang, Michael Singer, Xiaodong Sun, Jie Xu, Ali Tafreshi, M. Anthony Lewis, Huimin Xia, Kang Zhang
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
Luis Paz‐Ares, Alexander Luft, David Vicente, Ali Tafreshi, Mahmut Gümüş, Julien Mazières, Bárbara Hermes, Filiz Çay Şenler, Tibor Csőszi, Andrea Fülöp, Jerónimo Rafael Rodríguez‐Cid, Jonathan Wilson, Shunichi Sugawara, Terufumi Kato, Ki Hyeong Lee, Ying Cheng, Silvia Novello, Balázs Halmos, Xiaodong Li, Gregory M. Lubiniecki, Bilal Piperdi, Dariusz M. Kowalski
A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407
Luis Paz‐Ares, David Vicente, Ali Tafreshi, Andrew Robinson, Héctor Soto Parrà, Julien Mazières, Bárbara Hermes, İrfan Çiçin, Balazs Medgyasszay, Jerónimo Rafael Rodríguez‐Cid, Isamu Okamoto, Sung-Sook Lee, Rodryg Ramlau, Vladimir Vladimirov, Ying Cheng, Xuan Deng, Ying Zhang, Tuba Öcek Baş, Bilal Piperdi, Balázs Halmos
Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study
Silvia Novello, Dariusz M. Kowalski, Alexander Luft, Mahmut Gümüş, David Vicente, Julien Mazières, Jerónimo Rafael Rodríguez‐Cid, Ali Tafreshi, Ying Cheng, Ki Hyeong Lee, Alexander Golf, Shunichi Sugawara, Andrew Robinson, Balázs Halmos, Erin Jensen, Paul Schwarzenberger, M. Catherine Pietanza, Luis Paz‐Ares